Extended submission deadline!
Dear GoCART community,
EBMT and EHA released the second call for retrospective research proposals within the Scientific Excellence Work Package of the GoCART Coalition at the beginning of August.
We would like to inform you that the initial deadline for submission has been extended to Friday 7 October 2022.
The aim of the call is to promote the use of existing Registry data and other sources of real world data and to strengthen collaborations across stakeholders in the field of CAR T-cell therapies. Proposals for retrospective studies must be presented by collaborations of stakeholders involved in the GoCART Coalition.
If you would like to contribute to the advancement of the CAR T-cell therapy field and do you have a good study proposal, please submit your proposal using the form and send it to GoCART@ebmt.org.
Proposals that are received before the submission deadline will be evaluated by a selection committee with Prof Anna Sureda (President of the EBMT), Dr. Annalisa Ruggeri (Chair EBMT Cellular Therapies and Immunobiology Working Party), Prof. John Gribben (Past President of the EHA), Prof. Martin Dreyling (Board member of EHA) and Natacha Bolaños (Chair EBMT Patient Advocacy Committee). Proposals will be evaluated against four criteria: scientific impact, novelty, collaboration across stakeholders and feasibility of the proposal. In December 2022, the three winning proposals will be announced.
We remind you that EBMT will be economically supporting the selected studies that are proposed by noncommercial partners by providing the required resources to conduct the study. The EBMT business unit will draw up a budget for the conduct of any selected proposal that includes a pharmaceutical company.
Looking forward to an exciting scientific wave of proposals and discussions.
On behalf of EBMT,
Prof Dr Anna Sureda, President of the EBMT